Discover
llllllllllimsidolimab (ANB019) / AnaptysBioAnaptysBio Announces Second Quarter 2020 Financial Results and Provides Pipeline Updates (AnaptysBio Press Release) - Aug 10, 2020 - "Treatment of GPP by imsidolimab is being evaluated in the GALLOP Phase 2 trial, where additional clinical data and a regulatory update is anticipated in the fourth quarter of 2020."llllllllllIMU-935 / ImmunicImmunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters’ Option to Purchase Additional Shares (PRNewswire) - Aug 10, 2020 - "Immunic, Inc....announced the closing of an underwritten public offering of 5,750,000 shares of its common stock at a public offering price of $18.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 750,000 shares....The Company intends to use the net proceeds of the offering to fund the ongoing clinical development of its three lead product candidates, IMU-838, IMU-935 and IMU-856..."llllllllllBI 730357 / Boehringer IngelheimA Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is (clinicaltrials.gov) - Aug 14, 2020 - P2; N=180; Recruiting; Sponsor: Boehringer Ingelheim; Active, not recruiting --> Recruiting; N=87 --> 180
